Vigilant Biosciences Awarded Grant for Oral Cancer Diagnostic System

Posted: August 19, 2016
Edited by Dentaltown staff

FORT LAUDERDALE, Fla.—Vigilant Biosciences, a developer of solutions that aid in the early detection and intervention of cancer, has received a Phase I Small Business Innovation Research (SBIR) grant in the amount of US $219,454 from the National Institute of Dental and Craniofacial Research (NIDCR).

The 15-month grant will fund research by Vigilant Biosciences to develop a diagnostic test that utilizes optical imaging in combination with an oral rinse to detect CD44, a tumor-initiating and stem cell-associated biomarker for oral cancer.

Vigilant Biosciences' current product line is based on patented technology that measures an unprecedented combination of CD44 and total protein levels—markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse—to aid clinicians in the early detection and intervention of oral cancer.

The oral rinse procedure is easy to administer and non-invasive for the patient. Vigilant Biosciences' product line currently includes the OncAlert Labs OraMark test, a laboratory developed test available only through OncAlert Labs, a CLIA certified laboratory, and the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States.

"We are very pleased to receive this Phase I SBIR award from the NIDCR, as it supports the significance and further validation of the promise of our technology and its potential impact on cancer detection and intervention," said Matthew H.J. Kim, founder, chairman, and CEO of Vigilant Biosciences. "The proprietary science behind our tests uses unique biomarkers that can indicate the presence of oral and oropharyngeal cancer, often before physical symptoms are present. This grant will enable us to expand our approach to additional platforms and applications to meet the critical and growing need for earlier intervention of this disease and potentially other cancers."

The Phase I preclinical study will include in vitro work as well as human tissues from cancer patients and patients with benign disease of the throat.

Sponsors

Townie Perks

Townie® Poll

What do you use to take routine X-rays?


  

Site Help

Sally Gross, Member Services
Phone: +1-480-445-9710
Email: sally@farranmedia.com

Follow Dentaltown

Mobile App

WITH DENTALTOWN . . . NO DENTIST WILL EVER HAVE TO PRACTICE SOLO AGAIN®

WWW.DENTALTOWN.COM - WHERE THE DENTAL COMMUNITY LIVES®

9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 · Phone: +1-480-598-0001 · Fax: +1-480-598-3450
©1999-2019 Dentaltown, L.L.C., a division of Farran Media, L.L.C. · All Rights Reserved